journal Journal For International Medical Graduates Journal For International Medical Graduates California Institute of Behavioral Neurosciences and Psychology US https://www.cibnp.com 2832-9864 126 Articles The Quest for Optimal Therapy: Sofosbuvir and Ribavirin in Chronic Hepatitis C – A Systematic Review Monica Devi Yerramsetti Yerramsetti Monica Devi monicadevi.yerramsetti@gmail.com Olawale O. Olanisa Olanisa Olawale O. olawale.o.olanisa@jimgs.com Payal Jain Jain Payal payal.jain@jimgs.com Qasim S. Khan Khan Qasim S. qasimkhan.tk@gamil.com. Abhijith C Vemulapalli Vemulapalli Abhijith C abhijith.c.vemulapalli@jimgs.com Abanob A Elias Elias Abanob A aelias.cns@gmail.com Samia Rauf Butt Butt Samia Rauf samia.rauf.butt@jimgs.com California Institute of Behavioral Neurosciences and Psychology (United States) https://ror.org/01ytd2n62 19 09 2023 Received: 1992023 Copyright (c) 2023 Journal For International Medical Graduates 2023 Journal For International Medical Graduates Sofosbuvir Ribavirin Chronic Hepatitis-C Cirrhosis Safety Efficacy Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019;26(3):323-328. doi:10.1111/jvh.13034 Tang L, Kamat M, Shukla A, et al. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis. 2018;2018:9124604. Published 2018 Oct 1. doi:10.1155/2018/9124604 Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?. Clin Mol Hepatol. 2018;24(3):294-296. doi:10.3350/cmh.2018.1009 Butt N, Reema S, Ali Khan M, et al. Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus. 2019;11(4):e4458. Published 2019 Apr 14. doi:10.7759/cureus.4458 Kim YM, Kim SB, Song IH, et al. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol. 2018;24(3):311-318. doi:10.3350/cmh.2017.0070 Miyasaka A, Yoshida Y, Suzuki A, Masuda T, Okamoto H, Takikawa Y. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review. Medicine (Baltimore). 2020;99(41):e22650. doi:10.1097/MD.0000000000022650 Pellicelli A, Messina V, Giannelli V, et al. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. Gut Liver. 2020;14(3):357-367. doi:10.5009/gnl18269 Chen CC, Tung SY, Wei KL, et al. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc. 2020;119(1 Pt 3):532-537. doi:10.1016/j.jfma.2019.07.028 Xu XW, Wu XX, Chen KD, et al. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Medicine (Baltimore). 2018;97(38):e12403. doi:10.1097/MD.0000000000012403 Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020;20(1):929. Published 2020 Dec 4. doi:10.1186/s12879-020-05657-5 Jang ES, Kim KA, Kim YS, et al. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut Liver. 2020;14(6):775-782. doi:10.5009/gnl19260 Mita E, Liu LJ, Shing D, et al. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. Intern Med. 2023;62(10):1405-1414. doi:10.2169/internalmedicine.0067-22 Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. J Clin Exp Hepatol. 2019;9(1):4-12. doi:10.1016/j.jceh.2018.02.009 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect. 2021;9(4):e00811. doi:10.1002/prp2.811 Liu CH, Chen CY, Su WW, et al. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clin Mol Hepatol. 2021;27(4):575-588. doi:10.3350/cmh.2021.0155 Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother. 2020;121:109657. doi:10.1016/j.biopha.2019.109657 Han SY, Woo HY, Heo J, et al. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. Korean J Intern Med. 2021;36(3):544-556. doi:10.3904/kjim.2018.329 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372: n71. 10.1136/bmj. n71 https://www.ohri.ca/programs/clinical_epidemiolog y/oxford.asp. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials. https://jbi.global/critical-appraisal-tools. Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421-441. doi:10.4254/wjh.v11.i5.421 Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial [published correction appears in JAMA. 2013 Nov 13;310(18):1987. Dosage error in article text]. JAMA. 2013;310(8):804-811. doi:10.1001/jama.2013.109309 Wei B, Ji F, Yeo YH, et al. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5(1):e000207. Published 2018 Jun 29. doi:10.1136/bmjgast-2018-000207 Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon. 2014;14(11):e25540. Published 2014 Nov 23. doi:10.5812/hepatmon.25540 https://www.uspharmacist.com/article/the-evolving-management-of-hepatitis-c-virus#:~:text=Nonstructural%20Protein%205B%20(N S5B)%20Inhibitors,with%20other%20agents%20or% 20ribavirin Shiha G, Esmat G, Hassany M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019;68(4):721-728. doi:10.1136/gutjnl-2017-315906 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology. 2019;156(2):431-445. doi:10.1053/j.gastro.2018.10.024 Nakamura M, Kanda T, Haga Y, et al. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol. 2016;8(3):183-190. doi:10.4254/wjh.v8.i3.183 https://gastro.org/news/hepatitis-c-virus-sustained-virological-response-svr-following-treatment-best-practices/.